Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Biomed Res Int ; 2021: 6653747, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33681363

RESUMEN

OBJECTIVE: This study is set out to determine the relationship between IL-32 and radiosensitivity of esophageal squamous cell carcinoma (ESCC). METHODS: Western blot was adopted for measuring IL-32 expression in Eca-109 and TE-10 cells. Eca-109 and TE-10 cells with interference or overexpression of IL-32 were treated with the presence or absence of X-ray irradiation. Then, the use of CCK8 assay was to detect proliferation ability, and effects of IL-32 expression on radiosensitivity of ESCC were tested by colony formation assay. The cell apoptosis was detected using flow cytometry. STAT3 and p-STAT expression, and apoptotic protein Bax were detected by western blot. RESULTS: Colony formation assay and CCK8 assay showed that compared with the NC group without treatment, the growth of the ESCC cells, that is Eca-109 and TE-10, was significantly inhibited in the OE+IR group with highly expressed IL-32 and irradiation. In flow cytometry analysis, in Eca-109 and TE-10 cells, highly expressed IL-32 combined with irradiation significantly increased apoptosis compared with the control group. Highly expressed IL-32 has a synergistic effect with irradiation, inhibiting STAT3 and p-STAT3 expression and increasing apoptotic protein Bax expression. CONCLUSION: IL-32 can improve the radiosensitivity of ESCC cells by inhibiting the STAT3 pathway. Therefore, IL-32 can be used as a new therapeutic target to provide a new attempt for radiotherapy of ESCC.


Asunto(s)
Neoplasias Esofágicas , Carcinoma de Células Escamosas de Esófago , Interleucinas/inmunología , Proteínas de Neoplasias/inmunología , Tolerancia a Radiación/inmunología , Factor de Transcripción STAT3/inmunología , Transducción de Señal/inmunología , Línea Celular Tumoral , Neoplasias Esofágicas/inmunología , Neoplasias Esofágicas/patología , Neoplasias Esofágicas/radioterapia , Carcinoma de Células Escamosas de Esófago/inmunología , Carcinoma de Células Escamosas de Esófago/patología , Carcinoma de Células Escamosas de Esófago/radioterapia , Humanos
2.
Pathol Oncol Res ; 26(4): 2161-2168, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32170580

RESUMEN

The radioresistance of oesophageal squamous cell carcinoma (OSCC) is a critical factor leading to a poor prognosis among patients. The expression of PBX1 is abnormally high in a broad range of human tissues, and this gene plays a key role in tumour proliferation. This research intended to explore the radiosensitization of OSCC by silencing PBX1. The OSCC cell lines KYSE450 and KYSE150 were subjected to PBX1 silencing and/or irradiation (IR). Cell proliferation, colony formation, and apoptosis were tested to evaluate the radiosensitization ability of PBX1 silencing. The levels of STAT3 and p-STAT3 in the OSCC cells were tested by Western blotting. Furthermore, KYSE150 cells with or without PBX1 silencing were xenografted into nude mice with or without radiation exposure. Concomitant PBX1 silencing and IR can obviously suppress growth and enhance radiosensitivity in OSCC cells and xenografts. Moreover, the downregulation of PBX1 inhibits the expression of STAT3 and p-STAT3. The downregulation of PBX1 may increase radiosensitivity in OSCC cells and xenografts via the PBX1/STAT3 pathway. Our findings demonstrate that PBX1 may be a potential target for promoting the effect of radiation therapy in OSCC patients.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Neoplasias Esofágicas/radioterapia , Regulación Neoplásica de la Expresión Génica/efectos de la radiación , Factor de Transcripción 1 de la Leucemia de Células Pre-B/metabolismo , Tolerancia a Radiación , Factor de Transcripción STAT3/metabolismo , Animales , Apoptosis , Biomarcadores de Tumor/genética , Proliferación Celular , Neoplasias Esofágicas/genética , Neoplasias Esofágicas/metabolismo , Neoplasias Esofágicas/patología , Carcinoma de Células Escamosas de Esófago/genética , Carcinoma de Células Escamosas de Esófago/metabolismo , Carcinoma de Células Escamosas de Esófago/patología , Carcinoma de Células Escamosas de Esófago/radioterapia , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Factor de Transcripción 1 de la Leucemia de Células Pre-B/genética , Factor de Transcripción STAT3/genética , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Cancer Lett ; 483: 114-126, 2020 07 28.
Artículo en Inglés | MEDLINE | ID: mdl-32014456

RESUMEN

Radioresistance reduces the success of therapy for patients with ESCC. Enhancing our understanding of the cardinal principles of radioresistance may improve the response of patients to irradiation. MicroRNAs perform a key role in posttranscriptional regulation, which is linked with the response of tumors to irradiation. Here, we successfully constructed a radioresistant cell line model, ECA109R, from parental esophageal cancer cell line ECA109. We used RNA-Seq analysis and qRT-PCR to compare the miRNA expression profiles of the ECA109 and ECA109R cell lines. The results revealed that miR-450a-5p was downregulated in the radioresistant cells. Functional analysis indicated that miR-450a-5p increases cellular radiosensitivity and suppresses autophagy in ESCC cells. We utilized a luciferase reporter assay to identify the target gene, DUSP10, as an indispensable regulator of the p38 and SAPK/JNK signaling pathways. Upregulation or downregulation of DUSP10 expression could reverse the effects of miR-450a-5p overexpression or inhibition. Tumor xenograft experiments verified that miR-450a-5p overexpression could increase sensitivity to radiation therapy in vivo. In general, our findings indicate that miR-450a-5p is a latent radiosensitizer and may represent a potential novel therapeutic target for radioresistance in ESCC.


Asunto(s)
Fosfatasas de Especificidad Dual/metabolismo , Neoplasias Esofágicas/radioterapia , Carcinoma de Células Escamosas de Esófago/radioterapia , MicroARNs/metabolismo , Fosfatasas de la Proteína Quinasa Activada por Mitógenos/metabolismo , Tolerancia a Radiación , Animales , Apoptosis/efectos de la radiación , Autofagia/efectos de la radiación , Línea Celular Tumoral , Fosfatasas de Especificidad Dual/genética , Neoplasias Esofágicas/enzimología , Neoplasias Esofágicas/genética , Neoplasias Esofágicas/patología , Carcinoma de Células Escamosas de Esófago/enzimología , Carcinoma de Células Escamosas de Esófago/genética , Carcinoma de Células Escamosas de Esófago/patología , Regulación Neoplásica de la Expresión Génica , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , MicroARNs/genética , Fosfatasas de la Proteína Quinasa Activada por Mitógenos/genética , Tolerancia a Radiación/genética , Transducción de Señal , Ensayos Antitumor por Modelo de Xenoinjerto , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
4.
Med Sci Monit ; 25: 8587-8594, 2019 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-31725704

RESUMEN

BACKGROUND Breast cancer is one of the most frequently encountered malignancies in women. Although the prognosis is good for most breast cancer patients, little is known about the outcomes of breast carcinoma during pregnancy. The long-term results and predictors of survival of conservative breast surgery for breast cancer during pregnancy are especially unclear. MATERIAL AND METHODS Patients with primary diagnosis of breast cancer during pregnancy who received conservative breast surgery were recruited in this study from October 2009 to January 2015. Clinical data were collected and compared to individuals without associated pregnancies. The primary outcome disease-free survival (DFS) and the secondary outcome, overall survival (OS), were compared between the 2 groups (pregnant vs. nonpregnant women). Cox proportional hazards regression analysis was used to assess the potential predictors of survival for breast cancer patients during pregnancy. RESULTS Sixty-three pregnant patients underwent conservative breast carcinoma. The median gestational age was 26 weeks and the median age was 34 years. The nonpregnant group consists of 82 individuals with median age of 37 years. All the patients received chemotherapy after surgery. The follow-up period was 3 years. The 3-year DFS was 79.3% in the pregnant group and 81.7% in the nonpregnant group. The 3-year OS was 87.3% (pregnant) and 89% (nonpregnant), respectively. Multivariable analysis revealed that tumor stage and chemotherapy were independent predictors for survival. CONCLUSIONS Our study showed that conservative breast surgery is a reliable therapy for breast cancer patients during pregnancy, with similar DFS and OS compared to nonpregnant patients.


Asunto(s)
Neoplasias de la Mama/mortalidad , Complicaciones Neoplásicas del Embarazo/mortalidad , Adulto , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Estudios de Casos y Controles , China , Supervivencia sin Enfermedad , Femenino , Humanos , Mastectomía , Persona de Mediana Edad , Embarazo , Complicaciones Neoplásicas del Embarazo/cirugía , Pronóstico , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA